PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.18%
R&D growth while CRVO reduces spending. John Neff would investigate strategic advantage.
22.12%
G&A growth less than half of CRVO's 121.83%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
35.03%
Operating expenses growth while CRVO reduces costs. John Neff would investigate differences.
35.03%
Total costs growth while CRVO reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
14.84%
D&A growth while CRVO reduces D&A. John Neff would investigate differences.
-35.35%
EBITDA decline while CRVO shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Operating income decline while CRVO shows 46.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-15.72%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-37.55%
Pre-tax income decline while CRVO shows 48.37% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-37.55%
Net income decline while CRVO shows 48.37% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-34.88%
EPS decline while CRVO shows 48.50% growth. Joel Greenblatt would examine position.
-34.88%
Diluted EPS decline while CRVO shows 48.50% growth. Joel Greenblatt would examine position.
2.03%
Share count reduction below 50% of CRVO's 0.02%. Michael Burry would check for concerns.
2.03%
Diluted share reduction below 50% of CRVO's 0.02%. Michael Burry would check for concerns.